2 Beaten-Down Biotech Stocks: Are They Bargains Now?
It isn't easy being a drugmaker without any drugs to sell. As shareholders of these two biotech stocks have learned recently, it isn't easy to own shares of clinical-stage drugmakers, either.
Shares of these formerly high-flying biotech stocks crashed this year in response to serious setbacks. Recent setbacks aside, though, these drugmakers have given investors a lot more to be excited about than their recent stock market valuations would suggest. Let's dig in a little further to see if they could be bargain opportunities right now.
Data source: Yahoo! Finance.
Source Fool.com
